The transforming activity of SV40 large T-antigen (Tag) depends on its binding to cellular proteins involved in the control of the cell cycle (p53, pRb, p300..) and on the Jdomain region in the amino-terminus. We established transgenic lines expressing wild-type or Tag mutant proteins lacking one of the three transforming domains, to determine the respective contributions of these domains to hepatic tumour formation. Tag mutants with no pRb-binding domain or N-terminal fragment did not cause neoplastic liver abnormalities. The dl1137 Tag mutant protein, which inhibits pRb function without aecting p53, induced hepatic tumours. These tumours grew signi®cantly faster than those induced by wild-type Tag. Our results demonstrate dierent requirements for each of the inactivating functions of SV40 Tag in hepatocyte transformation and show that the loss of p53 function has only a moderate eect on hepatic tumour formation.
Introduction SV40 large T-antigen (Tag) is a transforming protein which disrupts the control of host cell growth by interacting with cellular proteins. Three physically separate regions of Tag are involved in its transforming activity: (i) the ®rst 82-amino acids of the Nterminal region, (ii) residues 105 ± 114, and (iii) the Cterminal region (amino acids 351 ± 626). Each of these domains inhibit cellular functions and are required to fully transform a variety of cells in vitro.
The activity of the N-terminal domain is the least well characterized. This domain is critical for cell transformation and tumour formation in transgenic mice and may have several independent transforming functions. It has been shown that the N-terminal region can restore the transforming function of an E1A mutant with no p300-binding activity (Yaciuk et al., 1991) , but there is no conclusive biochemical evidence of interaction between the N-terminus and characterized cellular proteins. The N-terminal domain also reduces phosphorylation of pRb-related proteins (p107 and p130) (Stubdal et al., 1996) and increases p130 degradation (Stubdal et al., 1997) . The ®rst 82 amino acids act as the J domain of DnaJ molecular chaperones and may be involved in the formation of multiprotein complexes (Srinivasan et al., 1997) .
The second transforming function of Tag involves pRb and pRb-related proteins (p107 and p130)-binding, and contains the LXCXE motif conserved in several transforming proteins, such as adenovirus E1A and HPV-16 E7 (Dyson et al., 1989; Moran, 1988) . Many studies have shown that the pRb-binding site must be intact for Tag to be fully oncogenic. Viral tumour formation may mimic the loss of pRb function, which occurs in several human tumours, including retinoblastoma, osteosarcoma, breast, lung and bladder carcinoma (for review, see Williams and Jacks, 1996) .
The third transforming activity of Tag has been mapped to the carboxy-terminus which contains a p53-binding domain. However this domain is sometimes not required for the transformation of certain cell types or for tumour formation in transgenic mice (Chen et al., 1992; Saenz Robles et al., 1994; Srinivasan et al., 1989) . Loss of p53 activity may be associated with tumour progression rather than tumour induction. Transgenic mice expressing the dl1137 Tag mutant protein, which contains the pRbbinding domain without the p53-binding region, develop brain tumours much more slowly than transgenic mice expressing the wild-type Tag (Saenz Robles et al., 1994) . This lower tumour growth rate is associated with a higher level of p53-dependent apoptosis which occurs in response to oncogenic events .
It has been shown that the carboxy-terminal region, containing sequences required for p53-Tag interaction, also interacts with members of the CBP family of transcription activators (CREB binding protein, p300 and p400) (Avantaggiati et al., 1996; Eckner et al., 1996; Lill et al., 1997a,b) . It has been suggested that p300-Tag complex formation may require the prior formation of a p53-Tag complex (Srinivasan et al., 1997) , because p300 and other CBP family members bind to and modulate p53 Gu et al., 1997; Lill et al., 1997a,b; Sang et al., 1997) . However it is not clear whether other Tag regions inhibit p300 function. Indeed Tag, but not Tag mutant deleted in residues 17 ± 27 (dl1135 mutant), restores transforming properties of E1A mutants which lack p300-binding activity (Yaciuk et al., 1991) . In addition, deletion of residues 98 ± 126 of Tag which impairs pRb-binding activity strongly aects the binding of Tag to p300 family members (Eckner et al., 1996) .
We investigated which of the transforming domains of Tag are involved in inducing hepatocarcinoma (HCC) in transgenic mice. We targeted the expression of three mutant Tag genes to hepatocytes using the antithrombin III promoter. The mutants were (i) the dl1135 mutant with deletion in the J domain, (ii) the dl1137 mutant which lacks the p53-and p300-binding domains and (iii) the K1 and K7 mutants which contain point mutations in the pRb-binding site. We analysed tumour induction in transgenic mice expressing these mutant proteins or the wild-type Tag protein (wtTag mice, also called ASV mice) (Dubois et al., 1991) and found that the amino-terminus of Tag was necessary and sucient to induce HCC. We also showed that the loss of p53 function had only a moderate eect on hepatic tumour formation.
Results
The pRb-binding domain is required for the hepatocytic transformation activity of SV40 Tag in vivo
We investigated whether inactivation of pRb by SV40 Tag was required for induction of hepatocellular carcinoma by producing transgenic mice that expressed either the K1 or the K7 Tag mutant protein, both of which lack the pRb-binding site (DeCaprio et al., 1988; Kalderon and Smith, 1984) but bind p53 and p300 (Figure 1 ). The K1 and K7 Tag mutant proteins were targeted to hepatocytes using the promoter/ enhancer of the human antithrombin III gene. Two homozygous lines expressing the transgene were established for each mutant. The labelling index (LI), based on the amount of bromodeoxyuridine (BrdU) incorporation, was used as a measure of the number of actively replicating hepatocytes. The LI of transgenic mice livers was similar to that of control livers regardless of the age of the mice (Table 1) . The relative liver weights of K1 or K7 transgenic mice and normal mice were almost identical ( Figure 2 ). Liver sections from 3-to 18-month-old transgenic mice were examined and were found to have no obvious histological dierences from normal livers ( Figure  3a) . Thus, the K1 and K7 mutants did not cause an abnormal hepatic phenotype.
As the lack of hepatocyte abnormalities might be due to weak expression of the K1 or K7 transgenes, we performed comparative Northern blot analyses with two wtTag transgenic model systems, previously shown to develop hepatocarcinoma, as a control (Allemand et al., 1995; Dubois et al., 1991) . All the K1 and K7 lines expressed more Tag mRNA than did the wtTag lines ( Figure 5 and data not shown). These transcripts were translated into protein as observed with Western blot analysis and in situ detection (data not shown).
Our analyses of K1 and K7 transgenic mice strongly suggest that the induction of hepatocarcinoma by SV40 Tag (Dubois et al., 1991) depends on there being an intact domain that can interact with pRb and pRb-related-proteins.
The N-terminal domain is critical for Tag hepatocarcinoma induction
We studied the involvement of the N-terminal domain of Tag in hepatocarcinogenesis by generating mice that expressed the dl1135 mutant protein in which amino acids 17 ± 27 are deleted ( Figure 1 ). Three transgenic lines expressing various levels of dl1135 mRNA and protein were maintained in a homozygous state and studied for 18 months. The mitotic activity of dl1135 transgenic liver, measured by BrdU incorporation, was similar to that of normal liver, regardless of the age of the mice (Table 1 ). The increase in liver weight of dl1135 mice over time was similar to that of normal mice and K1 mice ( Figure 2 ). Histological analysis of dl1135 liver sections also demonstrated the absence of hepatocyte abnormalities (Figure 3b ), and none of the 18-month-old dl1135 transgenic animals alive at the end of the experiment (50 mice in all) developed hepatocarcinoma. Northern ( Figure 5 ) and Western blots (data not shown) showed that the lack of tumour formation was not due to weak transgene expression. Moreover, the dl1135 protein was detected uniformly throughout hepatocyte nucleus by immunohistochemistry whereas the wtTag protein was not (data not shown). Our results, and those obtained with wtTag transgenic mice (Dubois et al., 1991) , show that the amino terminus is essential for hepatocarcinogenesis.
Restoration of wtTag tumoral phenotype in K1/dl1135 double transgenic mice
We tested whether sucient K1 or dl1135 protein was produced to inactivate p53, p300 or pRb by assessing tumour formation in double transgenic mice expressing both the K1 and dl1135 mutant proteins. Coexpression of both the K1 and dl1135 mutant proteins should mimic the expression of wild-type Tag. Therefore, the resulting double transgenic K1xdl1135 mice should have the same phenotype as wtTag transgenic mice. As expected, in all cases, K1xdl1135 mice developed hepatocarcinoma similarly to mice expressing the entire Tag protein (Figure 3c ).
The p53-binding domain of Tag is not required for hepatic tumour induction
The transforming activity of a third Tag mutant, dl1137, was assessed in mice. It encodes the 121 amino-terminal Figure 1 Wild-type SV40 Tag and the K1 and K7, dl1135 and dl1137 mutant proteins. Linear diagram of the wild-type (wt) Tag indicated J domain and pRb-and p53-binding regions. The K1 and K7 proteins each contain a single amino acid substitution (E107 ? L in K1 and E108 ? L in K7) in the pRb-binding region. The dl1135 mutant gene has two deletions, an in-frame deletion that results in the expression of Tag lacking amino acids 17 ± 27, including the p300-binding region, and a deletion within the intron that abolishes production of the small t-antigen. The dl1137 mutant gene encodes the amino-terminal region of Tag (121 residues) followed by 11 missense amino acids SV40 Tag mutants and Hepatocarcinogenesis M Bennoun et al amino acids of the protein, binds pRb and has no eect on the p53 level. One dl1137 founder expressed the truncated Tag protein accumulated mostly in the cytoplasm of the liver cells, because the nuclear localization signal had been removed. Unlike K1, K7 or dl1135 mice, all of the heterozygous dl1137 mice developed hepatocarcinoma and died within 1 year. We analysed homozygous mice obtained by crossing heterozygotes as we were unable to establish dl1137 homozygous lines. Liver tumours were induced earlier in dl1137 homozygous mice than in heterozygotes, leading to much more aggressive tumours and the rapid death of the mice (at 3 ± 6 months). This rapid disease development was correlated with a high rate of hepatocyte proliferation, as shown by the labelling index (Table 1) and hepatomegaly (Figure 2 ). The body weight of newborn homozygous mice was only 50 ± 70% that of their heterozygous littermates. There were large morphological dierences between the livers of heterozygous and homozygous transgenic mice. Liver sections from 6-month-old heterozygous mice had normal lobe structure with small nodules scattered throughout the hepatic parenchyma ( Figure  4a ). This pattern was similar to that of the livers of wtTag transgenic mice (Figure 4c ) with low transgene expression ( Figure 5, lane 1) . However, the anisokaryosis and anisocytosis observed in the preneoplastic stage of wtTag transgenic mice (Figure 4d , and Dubois et al., 1991) were not detected in dl1137 mice. This suggests that the cytological changes in the livers of wtTag transgenic mice may be due to p53 inhibition. After the age of 6 months, the nodules increased in size, causing large tumours similar to those of wtTag mice. Liver sections from 6-week-old dl1137 homozygous mice had morphological and cytological abnormalities with no lobe structure and small hepatocytes proliferating throughout the parenchyma, similar to the nodular cell population in both wtTag and heterozygous dl1137 mice ( Figure  4b ). Figure 4 Liver morphology of dl1137 or wild-type transgenic lines. Liver sections stained with hematein and eosin from (a) 6-month-old dl1137 heterozygous mice, (b) 6-week-old dl1137 homozygous mice, (c) 9-month-old wtTag1 mice, which expressed low levels of wild-type T antigen, (d) 6-week-old wtTag2 mice, which expressed high levels of wild-type T antigen
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Proliferating hepatocytes were presented in the livers of homozygous dl1137 mice earlier in hepatic development (before 2 weeks) than for heterozygotes. Preneoplastic signs such as anisocytosis, anisokaryosis, giant cells and liver apoptosis were not detected (Figure 4b and d) (Allemand et al., 1995; Dubois et al., 1991) . The tumours induced by dl1137 in homozygous mice grew signi®cantly faster than those induced by wild-type Tag (Figure 2) . Thus, liver oncogenesis occur more rapidly with the dl1137 mutant protein than with the wild-type Tag protein.
We produced nine more founders with the dl1137 mutant gene, but none of these transgenic mice transmitted the transgene to their ospring. This suggests that expression of the dl1137 in the liver may be lethal at early stages of development. This might explain why: (i) we obtained only one transgenic line that expressed the transgene; (ii) dl1137 gene expression was low in heterozygous transgenic mice; (iii) the development of hepatic tumours in dl1137 homozygous mice prevented the establishment of such a transgenic line.
Discussion
We used various Tag mutants in transgenic mice to determine the relative contribution of each Tag transforming function to hepatocarcinogenesis. We demonstrated that neither the K1 nor dl1135 mutant proteins, with mutations in the pRb-binding site and the J domain, respectively, caused HCC, whereas the Tag N-terminus (dl1137 mutant) was oncogenic. The absence of disease in the livers of K1 and dl1135 mice, and its presence in the livers of wtTag and dl1137 mice, shows that HCC formation requires both the LXCXE motif of Tag and its intact J domain.
Impairment of p53 function does not aect cell proliferation and the transformation of hepatocytes, as shown by the results for K1, K7 and dl1135. This is consistent with other studies. p53-null mice never develop hepatocarcinoma (Donehower et al., 1992) , even after treatment with the potent hepatocarcinogen, DMN (dimethyl nitrosamine) (Harvey et al., 1993) , or irradiation (Kemp et al., 1994) . Crossing wtTag mice with p53-null mice does not result in ospring with higher hepatocarcinoma growth rates (our unpublished data). Finally, transgenic mice expressing a dominant-negative inhibitor of p53 in hepatocytes do not develop liver abnormalities (Bowman et al., 1996) . Thus, loss of p53 function in liver does not appear to induce or promote hepatocellular carcinogenesis.
The lack of tumours with the K1 and K7 mutants suggests that the interaction of Tag with pRb, p107 and/or p130 proteins is required to change the growth pattern of the liver. pRb is a negative regulator of cell proliferation, as reintroduction of functional pRb into cells lacking wild-type pRb suppresses cell growth. In cycling cells, pRb is unphosphorylated and/or hypophosphorylated in the G 0 and early G 1 phases and then becomes hyperphosphorylated in late G 1 . The hypophosphorylated form of pRb is the active form and it interacts with proteins involved in cell growth control (i.e. E2F, cyclins of the D class). Phosphorylation inactivates pRb and causes the release of the associated cellular proteins. The role of pRb in the cell cycle progression of hepatocytes is unclear. In normal adult liver, pRb protein is barely detectable in quiescent hepatocytes. Its levels increase during liver regeneration after 70% partial hepatectomy. The protein remains primarily in the hyperphosphorylated form throughout regeneration (Fan et al., 1995) , suggesting that the concentration and phosphorylation status of pRb in hepatocytes are not correlated with the G 0 /G 1 transition. Our results suggest that functional pRb, p107 and/or p130 proteins are involved in the normal control of hepatocyte cell growth. However, the mechanism by which pRb or pRb-related proteins negatively regulate cell proliferation is unknown. We are currently exploring whether the inactivation of hepatic pRb by the dl1135 mutant protein aects entry into the G1 phase during liver regeneration.
The J domain contributes to Tag-induced HCC. The J domain has more than one biochemical activity (complementation of the transforming function of the p300-binding region of the E1A oncoprotein, association with hsc70, decrease in p107 and p130 levels) (Srinivasan et al., 1997; Stubdal et al., 1996 Stubdal et al., , 1997 Yaciuk et al., 1991) , so it is dicult to identify which one is involved in hepatic transformation. However, to our knowledge, there is no evidence that the J domain of Tag directly interacts with p300 or other CBP family members. In fact, the experiments demonstrating a requirement for the amino terminus of Tag in full p300-binding activity relied on comparative studies of full-length Tag and deletion mutant proteins (deletion of residues 17 ± 27 or residues 98 ± 126). It is unclear whether these deletions lead to conformational changes aecting the ability to bind p300 and other CBP family members. Results from dl1137 mice, which express the ®rst 121 amino acids of Tag, suggest that wild-type Tag protein may transform hepatocytes independently of p300/CBP inhibition. However, as the dl1135 mutant protein, which does not inhibit p300 function (Yaciuk et al., 1991) , did not induce hepatic tumours, Tag may require ecient pRb-and p300-inhibiting activities for hepatocarcinogenesis. We are currently testing whether p300 and other CBP family members bind to the dl1135 mutant protein in our transgenic mouse model.
Recent work has increased interest in the development of tumour models using transgenic animals expressing SV40 Tag. SV40 genome has been detected in various human tumours i.e. mesothelioma, meningioma, ependymoma, choroid plexus tumours) and in Figure 5 Expression of transgenes in liver from wild-type, K1, K7, dl1135 and dl1137 transgenic mice. Northern blot was performed with 20 mg of hepatic RNA from: (1) wtTag1 mice which expressed low levels of transgene and developed HCC at 6 months, (2) wtTag2 mice which expressed high levels of transgene and developed HCC at 3 months, (3) K1 homozygous mice, (4 ± 6) dl1135 homozygous mice, (7) dl1137 homozygous mice biological¯uids from healthy individuals (blood and sperm) (reviewed in Carbone et al., 1997) . Although the expression of SV40 genes has not been shown to cause such tumours, transgenic animal models may be a useful means of elucidating the mechanisms of carcinogenesis, leading to the development of new therapeutic strategies.
Materials and methods

Production and analysis of transgenic mice
The 700 bp 5'¯anking region of the human antithrombin III gene was fused to the sequence encoding the dl1137 (Pipas et al., 1983) , dl1135 (Pipas et al., 1983) , K1 or K7 (DeCaprio et al., 1988) SV40 Tag mutant proteins ( Figure  1 ). These DNA constructs were microinjected into fertilized eggs from a mating of B6D2F1 hybrids, as previously described (Dubois et al., 1991) . Transgenic founders were detected by Southern blot analysis of tail DNA using an SV40 early region probe. One dl1137, three dl1135, two K1 and two K7 founders carried transgenes. Expression of the transgenes was assessed by Northern blot analysis of total RNA which was isolated from mouse livers by the guanidine isothiocyanate method.
Histological analysis, immunostaining and Western blotting
Five mm-thick paran-embedded sections of liver (®xed in 4% formalin) from normal and transgenic mice were studied histologically. Sections were stained with hematoxilin and eosin. Liver sections from Tag mutant mice were immunostained with hamster anti-SV40 serum or anti-SV40 Tag monoclonal antibody PAb419 (gift from Dr E May), as previously described (Dubois et al., 1991) . For Western blots, proteins separated on SDS-protein gels were transferred to BA83 membranes (Schleicher & Schuell). The PAb419 monoclonal antibody was used to detect Tag mutants. Immune complexes were visualized by enhanced chemiluminescence (Amersham).
In vivo BrdU incorporation and measurement of the labelling index
Normal and transgenic mice were injected intraperitoneally with BrdU (0.1 mg/g body weight) (Sigma Chemical Co., St. Louis) in 0.9% NaCl. The livers were removed 2 h later and were rapidly frozen. Cryostat sections (5 mm thick) were ®xed in Carnoy for 10 min and then airdried. Liver sections were incubated for 45 min at 708C in 95% formamide/106SSC and were treated with protease (0.1 mg/ml) for 15 min at 378C. The slides were then incubated for 30 min in a 1% Tween 20/2% BSA, and labelled with the monoclonal antiBrdU antibody (Dako) by an indirect immunoperoxidase technique using an ABC Vectastain kit (Vector Laboratories). At least 200 hepatocytes were counted per slide, from two animals of each age. The labelling index (LI) is the number of BrdU-positive cells divided by the total number of cells, expressed as a percentage.
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